XKRX
000227
Market cap45mUSD
Oct 08, Last price
7,980.00KRW
1D
-1.72%
1Q
-7.32%
Jan 2017
26.33%
Name
Yuyu Pharma Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Yuyu Pharma, Inc. is dedicated to the development and commercialization of a wide spectrum of pharmaceutical products. Its comprehensive collection of prescription medications spans numerous therapeutic categories, offering treatments for conditions such as osteoporosis, disorders affecting brain and bone metabolism (including hypocalcemia), central and peripheral circulatory impairments, thromboembolism, respiratory issues, high blood pressure, pulmonary tuberculosis, arthritis, diabetic neuropathy, and eczematous dermatitis. The company further supplies other cardiovascular agents, antibiotics, and skeletal muscle relaxants. Beyond its prescription offerings, Yuyu Pharma also produces over-the-counter drugs and various health supplements. Originally established in 1941 as YuYu Inc., the company adopted its current name, Yuyu Pharma, Inc., in May 2008, and its corporate headquarters are located in Seoul, South Korea.
Key people
Ji Hun Bae
Assistant Managing Director
Jun Hui Cheon
Assistant Managing Director
Laxmikant Gharat
Assistant Managing Director
Jae Won Jang
Assistant Managing Director
Gyeong Won Kim
Assistant Managing Director
Chang Yun Lee
Assistant Managing Director
Seung Pyo Woo
Assistant Managing Director
Chae Yeong Yim
Assistant Managing Director
No Yong Park
Co-Chief Executive Officer, Director · since 2023
Won Sang Yoo
President, Co-Chief Executive Officer, Director · since 2023
Gang Seok Choi
Non-Executive Independent Director · since 2025
Sang Eon Joo
Non-Executive Independent Director · since 2022
Seung Wu Lee
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||